0.9000 -0.03 (-3.23%)
After hours: 5:11PM EDT
|Bid||0.9048 x 2200|
|Ask||0.9178 x 1100|
|Day's range||0.8500 - 0.9330|
|52-week range||0.8100 - 6.4200|
|Beta (5Y monthly)||3.01|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2020 - 09 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||1.50|
Mallinckrodt (MNK) gets a Complete Response Letter from the FDA for its NDA seeking approval for terlipressin to treat adults with hepatorenal syndrome type 1.
Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.